Incidence of chemotherapy-induced amenorrhea in hormone-sensitive breast cancer patients: the impact of addition of taxanes to anthracycline-based regimens
Adjuvant chemotherapy prolongs survival in patients with breast cancer, but it also causes side effects such as ovarian-function suppression. The incidence of chemotherapy-induced amenorrhea (CIA) varies depending on the patients' age, dose and the type of chemotherapy that they receive. CIA pr...
Gespeichert in:
| Veröffentlicht in: | Breast cancer research and treatment 2010-02, Vol.120 (1), p.245-251 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 251 |
|---|---|
| container_issue | 1 |
| container_start_page | 245 |
| container_title | Breast cancer research and treatment |
| container_volume | 120 |
| creator | Pérez-Fidalgo, José Alejandro Roselló, Susana García-Garré, Elisa Jordá, Esther Martín-Martorell, Paloma Bermejo, Begoña Chirivella, Isabel Guzman, Cecilia Lluch, Ana |
| description | Adjuvant chemotherapy prolongs survival in patients with breast cancer, but it also causes side effects such as ovarian-function suppression. The incidence of chemotherapy-induced amenorrhea (CIA) varies depending on the patients' age, dose and the type of chemotherapy that they receive. CIA produced by anthracycline-based regimens has been widely studied, but less is known about the incidence of CIA caused by the combined use of taxanes and anthracyclines. It has been suggested that tamoxifen might influence the maintenance of amenorrhea. However, most studies of CIA have explored series of patients with hormone-sensitive and hormone-resistant tumors, so data about CIA could be strongly influenced by endocrine adjuvant therapy. The aims of our study were to assess the incidence of CIA with the addition of taxanes to anthracyclines regimens in pre- or perimenopausal patients diagnosed with hormone-sensitive breast cancer and to determine predictive factors for CIA. A retrospective non-randomized study was conducted in the Hospital Clinico Universitario of Valencia, Spain. Three hundred and five premenopausal and perimenopausal patients were recruited between January 1998 and May 2005, 212 of whom had been treated with anthracycline-based regimens and 93 with a combination of anthracyclines and taxanes. Amenorrhea was permanent in 222 patients (93.7%) and menses returned in 6.3%. CIA was present in 75.5% of patients treated with anthracyclines and in 82.7% of patients treated with anthracyclines and taxanes. This difference did not reach statistical significance (p = 0.16). CIA appeared in 95% of patients older than 45 years, while the proportion of CIA decreased to 52% in patients younger than 40 years. This suggests age as an important predictive factor for CIA (p < 0.001). Although a slightly superior incidence of CIA in patients with hormone-sensitive tumors treated with combination regimens was observed, no statistically significant difference in incidence was found. Age was found to be the main predictive factor for CIA in both groups. |
| doi_str_mv | 10.1007/s10549-009-0426-x |
| format | Article |
| fullrecord | <record><control><sourceid>gale_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_00535369v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A356447011</galeid><sourcerecordid>A356447011</sourcerecordid><originalsourceid>FETCH-LOGICAL-c599t-e6dc19117d3a04cabfcbe391721e81837906d9688fff2f48a2094ffbd798f72c3</originalsourceid><addsrcrecordid>eNp9kt1u1DAQhSMEokvhAbiBCASIixTb-XHM3aoCWmklLqDXltcZb1wl9tb2VrvPwssyUVYtRQhFViLnO2c0MyfLXlJyRgnhnyIldSUKQvBUrCn2j7IFrXlZcEb542xBaMOLpiXNSfYsxmuCICfiaXZCRc1rJugi-3XptO3Aaci9yXUPo089BLU9FNZ1Ow1drkZwPoQeVG5d3vswegdFBBdtsreQrwOomHKt0CTkW5UsuBQ_5-iT23GrdJqsVdch7t30ndReOYh58rlyqQ9KH_Rg0XStIhYMsLFYMz7Pnhg1RHhxfJ9mV1-__Dy_KFbfv12eL1eFroVIBTSdpoJS3pWKVFqtjV5DKSgOAVrallyQphNN2xpjmKlaxYiojFl3XLSGM12eZh9n314NchvsqMJBemXlxXIlpztC6rIuG3FLkf0ws9vgb3YQkxxt1DAM2JDfRclLrNdUrUDyzV_ktd8Fh41IRlnViKrlCL2doY0aQFpnfMJpTJZyWdZNVXFCp6Jn_6Dw6WC0GrdhLN4_ELz_Q4CbG1If_bCbFhAfgnQGdfAxBjB3_VMip4zJOWM4AjyYMblHzatjY7v1CN294hgqBN4dARW1GkzAZNh4xzFW0RpTihybuYi_3AbC_YT-V_31LDLKS7UJaHz1gxFaEspFVbO6_A0EEPKd</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>212469487</pqid></control><display><type>article</type><title>Incidence of chemotherapy-induced amenorrhea in hormone-sensitive breast cancer patients: the impact of addition of taxanes to anthracycline-based regimens</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Pérez-Fidalgo, José Alejandro ; Roselló, Susana ; García-Garré, Elisa ; Jordá, Esther ; Martín-Martorell, Paloma ; Bermejo, Begoña ; Chirivella, Isabel ; Guzman, Cecilia ; Lluch, Ana</creator><creatorcontrib>Pérez-Fidalgo, José Alejandro ; Roselló, Susana ; García-Garré, Elisa ; Jordá, Esther ; Martín-Martorell, Paloma ; Bermejo, Begoña ; Chirivella, Isabel ; Guzman, Cecilia ; Lluch, Ana</creatorcontrib><description>Adjuvant chemotherapy prolongs survival in patients with breast cancer, but it also causes side effects such as ovarian-function suppression. The incidence of chemotherapy-induced amenorrhea (CIA) varies depending on the patients' age, dose and the type of chemotherapy that they receive. CIA produced by anthracycline-based regimens has been widely studied, but less is known about the incidence of CIA caused by the combined use of taxanes and anthracyclines. It has been suggested that tamoxifen might influence the maintenance of amenorrhea. However, most studies of CIA have explored series of patients with hormone-sensitive and hormone-resistant tumors, so data about CIA could be strongly influenced by endocrine adjuvant therapy. The aims of our study were to assess the incidence of CIA with the addition of taxanes to anthracyclines regimens in pre- or perimenopausal patients diagnosed with hormone-sensitive breast cancer and to determine predictive factors for CIA. A retrospective non-randomized study was conducted in the Hospital Clinico Universitario of Valencia, Spain. Three hundred and five premenopausal and perimenopausal patients were recruited between January 1998 and May 2005, 212 of whom had been treated with anthracycline-based regimens and 93 with a combination of anthracyclines and taxanes. Amenorrhea was permanent in 222 patients (93.7%) and menses returned in 6.3%. CIA was present in 75.5% of patients treated with anthracyclines and in 82.7% of patients treated with anthracyclines and taxanes. This difference did not reach statistical significance (p = 0.16). CIA appeared in 95% of patients older than 45 years, while the proportion of CIA decreased to 52% in patients younger than 40 years. This suggests age as an important predictive factor for CIA (p < 0.001). Although a slightly superior incidence of CIA in patients with hormone-sensitive tumors treated with combination regimens was observed, no statistically significant difference in incidence was found. Age was found to be the main predictive factor for CIA in both groups.</description><identifier>ISSN: 0167-6806</identifier><identifier>EISSN: 1573-7217</identifier><identifier>DOI: 10.1007/s10549-009-0426-x</identifier><identifier>PMID: 19575291</identifier><identifier>CODEN: BCTRD6</identifier><language>eng</language><publisher>Boston: Boston : Springer US</publisher><subject>Adjuvant treatment ; Adult ; Age Factors ; Amenorrhea ; Amenorrhea - chemically induced ; Amenorrhea - epidemiology ; Anthracyclines ; Anthracyclines - administration & dosage ; Anthracyclines - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Biological and medical sciences ; Breast cancer ; Breast Neoplasms - drug therapy ; Breast Neoplasms - pathology ; Brief Report ; Cancer ; Cancer patients ; Cancer research ; Cancer therapies ; Care and treatment ; Chemotherapy ; Female ; Female genital diseases ; Gynecology. Andrology. Obstetrics ; Health aspects ; Hormones ; Humans ; Incidence ; Mammary gland diseases ; Medical sciences ; Medicine ; Medicine & Public Health ; Menstruation ; Middle Aged ; Neoplasm Staging ; Neoplasms, Hormone-Dependent - drug therapy ; Neoplasms, Hormone-Dependent - pathology ; Non tumoral diseases ; Oncology ; Retrospective Studies ; Side effects ; Tamoxifen ; Taxoids - administration & dosage ; Taxoids - adverse effects ; Tumors</subject><ispartof>Breast cancer research and treatment, 2010-02, Vol.120 (1), p.245-251</ispartof><rights>Springer Science+Business Media, LLC. 2009</rights><rights>2015 INIST-CNRS</rights><rights>COPYRIGHT 2010 Springer</rights><rights>Springer Science+Business Media, LLC. 2010</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c599t-e6dc19117d3a04cabfcbe391721e81837906d9688fff2f48a2094ffbd798f72c3</citedby><cites>FETCH-LOGICAL-c599t-e6dc19117d3a04cabfcbe391721e81837906d9688fff2f48a2094ffbd798f72c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10549-009-0426-x$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10549-009-0426-x$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>230,314,778,782,883,27907,27908,41471,42540,51302</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22415573$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19575291$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-00535369$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Pérez-Fidalgo, José Alejandro</creatorcontrib><creatorcontrib>Roselló, Susana</creatorcontrib><creatorcontrib>García-Garré, Elisa</creatorcontrib><creatorcontrib>Jordá, Esther</creatorcontrib><creatorcontrib>Martín-Martorell, Paloma</creatorcontrib><creatorcontrib>Bermejo, Begoña</creatorcontrib><creatorcontrib>Chirivella, Isabel</creatorcontrib><creatorcontrib>Guzman, Cecilia</creatorcontrib><creatorcontrib>Lluch, Ana</creatorcontrib><title>Incidence of chemotherapy-induced amenorrhea in hormone-sensitive breast cancer patients: the impact of addition of taxanes to anthracycline-based regimens</title><title>Breast cancer research and treatment</title><addtitle>Breast Cancer Res Treat</addtitle><addtitle>Breast Cancer Res Treat</addtitle><description>Adjuvant chemotherapy prolongs survival in patients with breast cancer, but it also causes side effects such as ovarian-function suppression. The incidence of chemotherapy-induced amenorrhea (CIA) varies depending on the patients' age, dose and the type of chemotherapy that they receive. CIA produced by anthracycline-based regimens has been widely studied, but less is known about the incidence of CIA caused by the combined use of taxanes and anthracyclines. It has been suggested that tamoxifen might influence the maintenance of amenorrhea. However, most studies of CIA have explored series of patients with hormone-sensitive and hormone-resistant tumors, so data about CIA could be strongly influenced by endocrine adjuvant therapy. The aims of our study were to assess the incidence of CIA with the addition of taxanes to anthracyclines regimens in pre- or perimenopausal patients diagnosed with hormone-sensitive breast cancer and to determine predictive factors for CIA. A retrospective non-randomized study was conducted in the Hospital Clinico Universitario of Valencia, Spain. Three hundred and five premenopausal and perimenopausal patients were recruited between January 1998 and May 2005, 212 of whom had been treated with anthracycline-based regimens and 93 with a combination of anthracyclines and taxanes. Amenorrhea was permanent in 222 patients (93.7%) and menses returned in 6.3%. CIA was present in 75.5% of patients treated with anthracyclines and in 82.7% of patients treated with anthracyclines and taxanes. This difference did not reach statistical significance (p = 0.16). CIA appeared in 95% of patients older than 45 years, while the proportion of CIA decreased to 52% in patients younger than 40 years. This suggests age as an important predictive factor for CIA (p < 0.001). Although a slightly superior incidence of CIA in patients with hormone-sensitive tumors treated with combination regimens was observed, no statistically significant difference in incidence was found. Age was found to be the main predictive factor for CIA in both groups.</description><subject>Adjuvant treatment</subject><subject>Adult</subject><subject>Age Factors</subject><subject>Amenorrhea</subject><subject>Amenorrhea - chemically induced</subject><subject>Amenorrhea - epidemiology</subject><subject>Anthracyclines</subject><subject>Anthracyclines - administration & dosage</subject><subject>Anthracyclines - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Biological and medical sciences</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - pathology</subject><subject>Brief Report</subject><subject>Cancer</subject><subject>Cancer patients</subject><subject>Cancer research</subject><subject>Cancer therapies</subject><subject>Care and treatment</subject><subject>Chemotherapy</subject><subject>Female</subject><subject>Female genital diseases</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Health aspects</subject><subject>Hormones</subject><subject>Humans</subject><subject>Incidence</subject><subject>Mammary gland diseases</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Menstruation</subject><subject>Middle Aged</subject><subject>Neoplasm Staging</subject><subject>Neoplasms, Hormone-Dependent - drug therapy</subject><subject>Neoplasms, Hormone-Dependent - pathology</subject><subject>Non tumoral diseases</subject><subject>Oncology</subject><subject>Retrospective Studies</subject><subject>Side effects</subject><subject>Tamoxifen</subject><subject>Taxoids - administration & dosage</subject><subject>Taxoids - adverse effects</subject><subject>Tumors</subject><issn>0167-6806</issn><issn>1573-7217</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9kt1u1DAQhSMEokvhAbiBCASIixTb-XHM3aoCWmklLqDXltcZb1wl9tb2VrvPwssyUVYtRQhFViLnO2c0MyfLXlJyRgnhnyIldSUKQvBUrCn2j7IFrXlZcEb542xBaMOLpiXNSfYsxmuCICfiaXZCRc1rJugi-3XptO3Aaci9yXUPo089BLU9FNZ1Ow1drkZwPoQeVG5d3vswegdFBBdtsreQrwOomHKt0CTkW5UsuBQ_5-iT23GrdJqsVdch7t30ndReOYh58rlyqQ9KH_Rg0XStIhYMsLFYMz7Pnhg1RHhxfJ9mV1-__Dy_KFbfv12eL1eFroVIBTSdpoJS3pWKVFqtjV5DKSgOAVrallyQphNN2xpjmKlaxYiojFl3XLSGM12eZh9n314NchvsqMJBemXlxXIlpztC6rIuG3FLkf0ws9vgb3YQkxxt1DAM2JDfRclLrNdUrUDyzV_ktd8Fh41IRlnViKrlCL2doY0aQFpnfMJpTJZyWdZNVXFCp6Jn_6Dw6WC0GrdhLN4_ELz_Q4CbG1If_bCbFhAfgnQGdfAxBjB3_VMip4zJOWM4AjyYMblHzatjY7v1CN294hgqBN4dARW1GkzAZNh4xzFW0RpTihybuYi_3AbC_YT-V_31LDLKS7UJaHz1gxFaEspFVbO6_A0EEPKd</recordid><startdate>20100201</startdate><enddate>20100201</enddate><creator>Pérez-Fidalgo, José Alejandro</creator><creator>Roselló, Susana</creator><creator>García-Garré, Elisa</creator><creator>Jordá, Esther</creator><creator>Martín-Martorell, Paloma</creator><creator>Bermejo, Begoña</creator><creator>Chirivella, Isabel</creator><creator>Guzman, Cecilia</creator><creator>Lluch, Ana</creator><general>Boston : Springer US</general><general>Springer US</general><general>Springer</general><general>Springer Nature B.V</general><general>Springer Verlag</general><scope>FBQ</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>1XC</scope><scope>VOOES</scope></search><sort><creationdate>20100201</creationdate><title>Incidence of chemotherapy-induced amenorrhea in hormone-sensitive breast cancer patients: the impact of addition of taxanes to anthracycline-based regimens</title><author>Pérez-Fidalgo, José Alejandro ; Roselló, Susana ; García-Garré, Elisa ; Jordá, Esther ; Martín-Martorell, Paloma ; Bermejo, Begoña ; Chirivella, Isabel ; Guzman, Cecilia ; Lluch, Ana</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c599t-e6dc19117d3a04cabfcbe391721e81837906d9688fff2f48a2094ffbd798f72c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Adjuvant treatment</topic><topic>Adult</topic><topic>Age Factors</topic><topic>Amenorrhea</topic><topic>Amenorrhea - chemically induced</topic><topic>Amenorrhea - epidemiology</topic><topic>Anthracyclines</topic><topic>Anthracyclines - administration & dosage</topic><topic>Anthracyclines - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Biological and medical sciences</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - pathology</topic><topic>Brief Report</topic><topic>Cancer</topic><topic>Cancer patients</topic><topic>Cancer research</topic><topic>Cancer therapies</topic><topic>Care and treatment</topic><topic>Chemotherapy</topic><topic>Female</topic><topic>Female genital diseases</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Health aspects</topic><topic>Hormones</topic><topic>Humans</topic><topic>Incidence</topic><topic>Mammary gland diseases</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Menstruation</topic><topic>Middle Aged</topic><topic>Neoplasm Staging</topic><topic>Neoplasms, Hormone-Dependent - drug therapy</topic><topic>Neoplasms, Hormone-Dependent - pathology</topic><topic>Non tumoral diseases</topic><topic>Oncology</topic><topic>Retrospective Studies</topic><topic>Side effects</topic><topic>Tamoxifen</topic><topic>Taxoids - administration & dosage</topic><topic>Taxoids - adverse effects</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pérez-Fidalgo, José Alejandro</creatorcontrib><creatorcontrib>Roselló, Susana</creatorcontrib><creatorcontrib>García-Garré, Elisa</creatorcontrib><creatorcontrib>Jordá, Esther</creatorcontrib><creatorcontrib>Martín-Martorell, Paloma</creatorcontrib><creatorcontrib>Bermejo, Begoña</creatorcontrib><creatorcontrib>Chirivella, Isabel</creatorcontrib><creatorcontrib>Guzman, Cecilia</creatorcontrib><creatorcontrib>Lluch, Ana</creatorcontrib><collection>AGRIS</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><jtitle>Breast cancer research and treatment</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pérez-Fidalgo, José Alejandro</au><au>Roselló, Susana</au><au>García-Garré, Elisa</au><au>Jordá, Esther</au><au>Martín-Martorell, Paloma</au><au>Bermejo, Begoña</au><au>Chirivella, Isabel</au><au>Guzman, Cecilia</au><au>Lluch, Ana</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Incidence of chemotherapy-induced amenorrhea in hormone-sensitive breast cancer patients: the impact of addition of taxanes to anthracycline-based regimens</atitle><jtitle>Breast cancer research and treatment</jtitle><stitle>Breast Cancer Res Treat</stitle><addtitle>Breast Cancer Res Treat</addtitle><date>2010-02-01</date><risdate>2010</risdate><volume>120</volume><issue>1</issue><spage>245</spage><epage>251</epage><pages>245-251</pages><issn>0167-6806</issn><eissn>1573-7217</eissn><coden>BCTRD6</coden><abstract>Adjuvant chemotherapy prolongs survival in patients with breast cancer, but it also causes side effects such as ovarian-function suppression. The incidence of chemotherapy-induced amenorrhea (CIA) varies depending on the patients' age, dose and the type of chemotherapy that they receive. CIA produced by anthracycline-based regimens has been widely studied, but less is known about the incidence of CIA caused by the combined use of taxanes and anthracyclines. It has been suggested that tamoxifen might influence the maintenance of amenorrhea. However, most studies of CIA have explored series of patients with hormone-sensitive and hormone-resistant tumors, so data about CIA could be strongly influenced by endocrine adjuvant therapy. The aims of our study were to assess the incidence of CIA with the addition of taxanes to anthracyclines regimens in pre- or perimenopausal patients diagnosed with hormone-sensitive breast cancer and to determine predictive factors for CIA. A retrospective non-randomized study was conducted in the Hospital Clinico Universitario of Valencia, Spain. Three hundred and five premenopausal and perimenopausal patients were recruited between January 1998 and May 2005, 212 of whom had been treated with anthracycline-based regimens and 93 with a combination of anthracyclines and taxanes. Amenorrhea was permanent in 222 patients (93.7%) and menses returned in 6.3%. CIA was present in 75.5% of patients treated with anthracyclines and in 82.7% of patients treated with anthracyclines and taxanes. This difference did not reach statistical significance (p = 0.16). CIA appeared in 95% of patients older than 45 years, while the proportion of CIA decreased to 52% in patients younger than 40 years. This suggests age as an important predictive factor for CIA (p < 0.001). Although a slightly superior incidence of CIA in patients with hormone-sensitive tumors treated with combination regimens was observed, no statistically significant difference in incidence was found. Age was found to be the main predictive factor for CIA in both groups.</abstract><cop>Boston</cop><pub>Boston : Springer US</pub><pmid>19575291</pmid><doi>10.1007/s10549-009-0426-x</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0167-6806 |
| ispartof | Breast cancer research and treatment, 2010-02, Vol.120 (1), p.245-251 |
| issn | 0167-6806 1573-7217 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_00535369v1 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Adjuvant treatment Adult Age Factors Amenorrhea Amenorrhea - chemically induced Amenorrhea - epidemiology Anthracyclines Anthracyclines - administration & dosage Anthracyclines - adverse effects Antineoplastic Combined Chemotherapy Protocols - adverse effects Biological and medical sciences Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - pathology Brief Report Cancer Cancer patients Cancer research Cancer therapies Care and treatment Chemotherapy Female Female genital diseases Gynecology. Andrology. Obstetrics Health aspects Hormones Humans Incidence Mammary gland diseases Medical sciences Medicine Medicine & Public Health Menstruation Middle Aged Neoplasm Staging Neoplasms, Hormone-Dependent - drug therapy Neoplasms, Hormone-Dependent - pathology Non tumoral diseases Oncology Retrospective Studies Side effects Tamoxifen Taxoids - administration & dosage Taxoids - adverse effects Tumors |
| title | Incidence of chemotherapy-induced amenorrhea in hormone-sensitive breast cancer patients: the impact of addition of taxanes to anthracycline-based regimens |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T23%3A23%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Incidence%20of%20chemotherapy-induced%20amenorrhea%20in%20hormone-sensitive%20breast%20cancer%20patients:%20the%20impact%20of%20addition%20of%20taxanes%20to%20anthracycline-based%20regimens&rft.jtitle=Breast%20cancer%20research%20and%20treatment&rft.au=P%C3%A9rez-Fidalgo,%20Jos%C3%A9%20Alejandro&rft.date=2010-02-01&rft.volume=120&rft.issue=1&rft.spage=245&rft.epage=251&rft.pages=245-251&rft.issn=0167-6806&rft.eissn=1573-7217&rft.coden=BCTRD6&rft_id=info:doi/10.1007/s10549-009-0426-x&rft_dat=%3Cgale_hal_p%3EA356447011%3C/gale_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=212469487&rft_id=info:pmid/19575291&rft_galeid=A356447011&rfr_iscdi=true |